XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating Expenses:        
Research and development $ 8,268 $ 3,675 $ 23,884 $ 12,999
General and administrative 4,357 1,548 10,367 3,791
Total operating expenses 12,625 5,223 34,251 16,790
Loss from operations (12,625) (5,223) (34,251) (16,790)
Other income (expense):        
Grant income 5,947 3,037 18,236 12,375
Change in the fair value of the derivative liability       2,209
Change in the fair value of the Simple Agreements for Future Equity   (932)   (1,976)
Other (expense) income, net 55 8 (182) 256
Gain on debt extinguishment       443
Interest expense, net (2)   (18) (894)
Total other income, net 6,000 2,113 18,036 12,413
Net loss (6,625) (3,110) (16,215) (4,377)
Cumulative preferred stock dividends   (1,859)   (4,326)
Net loss attributable to common stockholders (6,625) (4,969) (16,215) (8,703)
Unrealized loss on foreign currency translation (1) (3) (3) (9)
Total comprehensive loss $ (6,626) $ (3,113) $ (16,218) $ (4,386)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.29) $ (8.12) $ (0.71) $ (14.87)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.29) $ (8.12) $ (0.71) $ (14.87)
Weighted-average common shares outstanding, basic (in shares) 23,024,026 611,680 22,684,309 585,320
Weighted-average common shares outstanding, diluted (in shares) 23,024,026 611,680 22,684,309 585,320